Affiliation:
1. Tehran University of Medical Sciences Department of Clinical Laboratory Sciences Tehran Iran
2. Peoples\' Friendship University of Russia Department of Research and innovation Moscow Russian Federation
3. Tehran University of Medical Sciences Department of Hematology and Transfusion Medicine Tehran Iran
4. Kermanshah University of Medical Sciences Sleep Disorders Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. Kermanshah Iran
5. Kurdistan University of Medical Sciences Liver and Digestive Research Center Sanandij Iran
Abstract
Introduction:
Adipokine irregularity leads to inflammation, endothelial
dysfunction, insulin resistance (IR), and Non-Alcoholic Fatty Liver Disease (NAFLD).
Previous studies linked NOV/CCN3 to obesity, IR, and inflammation, but no research
has explored the connection between CCN3 serum levels and NAFLD.
Methods:
This case-control study assessed CCN3, IL-6, adiponectin, and TNF-α
serum levels in 80 NAFLD patients and 80 controls using ELISA kits. Biochemical
parameters were measured with commercial kits and an auto analyzer.
Results:
NAFLD patients exhibited significantly higher CCN3 (2399.85 ± 744.53 vs.
1712.84 ± 478.19 ng/ml), TNF-α, and IL-6 levels, and lower adiponectin levels
compared to controls (P<0.0001). In the NAFLD group, CCN3 showed positive
correlations with FBG, insulin, HOMA-IR, and TNF-α. Binary logistic regression
analysis revealed increased NAFLD risk in the adjusted model (OR [95% CI] = 1.220
[1.315 –1.131]). A CCN3 cut-off value of 1898.0050 pg/mL differentiated NAFLD
patients from controls with 78.8% sensitivity and 73.2% specificity.
Conclusion:
It was found that elevated CCN3 serum levels directly correlate with NAFLD incidence
and inflammation markers (IL-6 and TNF-α). CCN3 could serve as a potential
biomarker for NAFLD, but further research is needed to validate this finding and
assess its clinical utility.
Publisher
Bentham Science Publishers Ltd.